Share on StockTwits

Novo Nordisk A/S (NYSE:NVO) was the recipient of unusually large options trading on Friday. Stock traders purchased 222 call options on the company, Stock Ratings News reports. This represents an increase of 353% compared to the average volume of 49 call options.

Separately, analysts at Zacks reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 23rd. They now have a $48.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $489.00.

Shares of Novo Nordisk A/S (NYSE:NVO) traded up 0.05% on Friday, hitting $44.34. 1,089,399 shares of the company’s stock traded hands. Novo Nordisk A/S has a 52 week low of $32.20 and a 52 week high of $48.42. The stock’s 50-day moving average is $45.81 and its 200-day moving average is $44.3. The company has a market cap of $117.2 billion and a P/E ratio of 25.80.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Thursday, August 7th. The company reported $0.48 EPS for the quarter, missing the Thomson Reuters consensus estimate of $2.60 by $2.12. The company had revenue of $21.63 billion for the quarter, compared to the consensus estimate of $21.86 billion. During the same quarter in the prior year, the company posted $12.45 earnings per share. The company’s quarterly revenue was up 1.2% on a year-over-year basis. Analysts expect that Novo Nordisk A/S will post $1.84 EPS for the current fiscal year.

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products.

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with Analyst Ratings Network's FREE daily email newsletter.